CAH: Core Pharmaceutical Trends And Automation Will Shape Upcoming Earnings Performance

Key Takeaways

• Growth in pharmaceuticals and specialty distribution is driven by demographic trends, with diversification into specialty and home healthcare strengthening future earnings potential.
  
• Efficiency gains from automation and portfolio optimization are expected to improve margins, cash flow, and profit resilience amid ongoing healthcare industry changes.
  
• Increasing regulatory pressures, competitive threats, customer dependence, and evolving reimbursement risks could compress margins and constrain Cardinal Health's long-term growth prospects.

Catalysts

Operates as a healthcare services and products company in the United States, Canada, Europe, Asia, and internationally.

• Cardinal Health is well-positioned to benefit from increasing global demand for pharmaceuticals and medical supplies driven by an aging population and the rising prevalence of chronic diseases, which is leading to robust pharmaceutical volumes and consistent revenue growth in core and specialty distribution-positively impacting future top-line revenue.
  
• The company's investments in automation, advanced supply chain technology, and new distribution centers are expected to deliver long-term operational efficiencies and cost savings, supporting improved net margins and free cash flow as healthcare shifts to value-based and outpatient models.
  
• Strategic expansion into higher-margin specialty businesses, including acquisitions in multi-specialty MSO platforms (e.g., Solaris Health), specialty pharma, and biopharma solutions, should accelerate long-term profit growth, diversify revenue streams, and enhance overall earnings resilience.
  
• The strong performance and continued investment in Other growth businesses such as at-Home Solutions, Nuclear and Precision Health, and OptiFreight Logistics aligns with the growing trend of outpatient and home healthcare-underpinning diversified revenue growth and supporting margin expansion.
  
• Ongoing efforts to optimize the generic drug portfolio and scale Cardinal Health-branded medical products are yielding higher profitability versus branded counterparts and are expected to further enhance gross profit and operating margins, reinforcing long-term earnings growth.

Cardinal Health Future Earnings and Revenue Growth

Assumptions

• Analysts are assuming Cardinal Health's revenue will grow by 9.0% annually over the next 3 years.
• Analysts assume that profit margins will increase from 0.7% today to 0.8% in 3 years time.
• Analysts expect earnings to reach $2.2 billion (and earnings per share of $10.04) by about September 2028, up from $1.6 billion today. The analysts are largely in agreement about this estimate.
• In order for the above numbers to justify the analysts price target, the company would need to trade at a PE ratio of 22.5x on those 2028 earnings, down from 23.1x today. This future PE is greater than the current PE for the US Healthcare industry at 21.0x.
• Analysts expect the number of shares outstanding to decline by 1.33% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 6.78%, as per the Simply Wall St company report.

Cardinal Health Future Earnings Per Share Growth

Risks

• Increasing government regulation and pricing scrutiny, as referenced by the company managing through "regulatory uncertainty" and "the implementation of tariffs," could compress distribution margins and impact net margins and earnings over the long term.
  
• Heightened competition from peers and potential loss or expiration of major customer contracts, as seen in the "previously announced customer contract expiration," could limit future revenue growth and pressure operating earnings.
  
• Ongoing tariff headwinds and global supply chain risks remain substantial, with GMPD segment guidance assuming a "$50 million to $75 million headwind to our results in fiscal '26 from tariffs," while further volatility could drive increased costs and impact consolidated margins and net income.
  
• Increasing consolidation and vertical integration among healthcare providers, payers, and retailers-combined with Cardinal's dependence on major customer relationships highlighted by the impact of contract expirations-may compress revenue streams and erode gross profit over time.
  
• Potential reimbursement changes and government bidding programs, such as referenced "potential changes in the reimbursement environment" and "competitive bidding coming back," specifically in the at-Home Solutions segment, could reduce top-line growth and profitability within key business lines.

Valuation

• The analysts have a consensus price target of $180.462 for Cardinal Health based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $203.0, and the most bearish reporting a price target of just $150.0.
• In order for you to agree with the analyst's consensus, you'd need to believe that by 2028, revenues will be $288.0 billion, earnings will come to $2.2 billion, and it would be trading on a PE ratio of 22.5x, assuming you use a discount rate of 6.8%.
• Given the current share price of $150.94, the analyst price target of $180.46 is 16.4% higher.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.